Navigation Links
Amgen's Full Year 2012 Revenues Increased 11 Percent To $17.3 Billion And Adjusted Earnings Per Share (EPS) Increased 22 Percent To $6.51
Date:1/23/2013

add due to rounding2013 GuidanceFor the full year 2013, the Company expects:

  • Total revenues to be in the range of $17.8 billion to $18.2 billion and adjusted EPS to be in the range of $6.85 to $7.15.
  • Adjusted tax rate to be in the range of 14 percent to 15 percent. This reflects the impact of the foreign tax credit associated with the Puerto Rico excise tax. Excluding the Puerto Rico excise tax, Amgen expects the adjusted tax rate for 2013 to be in the range of 17 percent to 18 percent.
  • Capital expenditures to be approximately $700 million.
  • Product and Pipeline Update

  • AMG 145:  The Company recently initiated Phase 3 studies in subjects with high levels of LDL cholesterol.
  • Trebananib (AMG 386):  Enrollment has resumed for the Phase 3 study in recurrent ovarian cancer that was previously suspended due to DOXIL® (doxorubicin HCl liposome injection) supply issues.
  • Aranesp:  The Company announced top-line results of the Phase 3 RED-HF® (Reduction of Events With Darbepoetin Alfa in Heart Failure) Trial.
  • deCODE Genetics:  The Company completed the acquisition of deCODE Genetics in December 2012.
  • Non-GAAP Financial Measures
    The Adjusted non-GAAP (U.S. Generally Accepted Accounting Principles) financial measures included above for the three and twelve months ended Dec. 31, 2012 and 2011 exclude, for the applicable periods, certain expenses related to acquisitions, cost-savings initiatives, various legal proceedings, non-cash interest expense associated with our convertible notes and certain other adjustments, as applicable. These adjustments and other items are presented on the attached reconciliations.

    Management has presented its operating results in accordance with GAAP and on an "adjusted" (or non-GAAP) basis and Free Cash Flow which is a non-GAAP financial measure for the three and twelve months ended Dec. 31, 2012 and
    '/>"/>

    SOURCE Amgen
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

    Related medicine technology :

    1. IRIDEX Announces Preliminary Unaudited Revenues for 2012 Fourth Quarter and Year End
    2. MDHI Receives Term Sheet for Working Capital and Acquisition Financing -- Company Hits Profitability on Recurring Revenues
    3. Groupe Athena, Inc. Reports Record First Quarter Revenues, Adoption Of IFRS Accounting Standard In Anticipation Of Applying For Listing On The NASDAQ Bulletin Board
    4. InfuSystem Holdings, Inc. Reports $14.1 Million of Revenues for the Second Quarter of 2012; Announces Annualized Cost Savings in Excess of $1 million
    5. AMILPAR - Revenues Grow 18% and EBITDA Increases 19% in 1H12
    6. Volcano Corporation Reports 13 Percent Growth In Second Quarter Revenues; FFR Disposable Revenues Increase 38 Percent
    7. Amgens Second Quarter 2012 Revenues Increased 13 Percent To $4.5 Billion And Adjusted Earnings Per Share (EPS) Increased 34 Percent To $1.83
    8. CitiusTech Announces H1 2012 Results - 65% Growth in Half Year Revenues
    9. Herborium Group Reports Record 6 Month Revenues
    10. InfuSystem Holdings, Inc. Reports $14.3 Million of Revenues And $1.6 Million Of EBITDA For The First Quarter Of 2012
    11. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/20/2014)... 2014   Ventana Medical Systems, Inc.  (Ventana), ... that its VENTANA System for Primary Diagnosis 1 ... Union for routine pathology, including primary diagnosis with ... Virtuoso software coupled with either the VENTANA iScan ... provides automated digital slide creation, case management and ...
    (Date:8/20/2014)... 2014 ApolloDx™ today announced it will unveil ... special event at the company,s office in ... 2014. The event, which will start at 10:00 a.m., ... www.apollodx.com .    "We believe our mobile ... Bauer , Co-Founder and Managing Partner of ApolloDx. In ...
    (Date:8/20/2014)... SAN DIEGO , Aug. 20, 2014 ... molecular diagnostics, announced today that results from two clinical ... (IPV) conference for the Company,s urine-based diagnostic test for ... (HPV). The IPV conference is scheduled to take place ... st to 25 th . Additionally, a new ...
    Breaking Medicine Technology:Full digitization of the anatomic pathology lab is here with the VENTANA System for Primary Diagnosis 2Full digitization of the anatomic pathology lab is here with the VENTANA System for Primary Diagnosis 3Trovagene Provides Update on Its Urine-Based HPV Test 2Trovagene Provides Update on Its Urine-Based HPV Test 3
    ... 2007 /PRNewswire-USNewswire/ -- The,following statement may be attributed ... Medical Research (CAMR): , "In the face of ... the stroke of his veto pen deliberately to ... well as endanger,the future health and well being ...
    ... - Elixir,Pharmaceuticals, Inc., announced today the publication ... (mitiglinide calcium,hydrate) monotherapy, or combination therapy with ... meals. The data were,published in the Abstract ... Scientific Sessions in Chicago, Illinois.,Glufast is an ...
    Cached Medicine Technology:President Bush Ignores America's Plea for Support of Stem Cell,Research 2Elixir Pharmaceuticals Announces Clinical Data at American Diabetes,Association Conference Highlighting Ability of Glufast to Maintain,Glycemic Control in Patients with Type 2 Diabetes 2Elixir Pharmaceuticals Announces Clinical Data at American Diabetes,Association Conference Highlighting Ability of Glufast to Maintain,Glycemic Control in Patients with Type 2 Diabetes 3Elixir Pharmaceuticals Announces Clinical Data at American Diabetes,Association Conference Highlighting Ability of Glufast to Maintain,Glycemic Control in Patients with Type 2 Diabetes 4Elixir Pharmaceuticals Announces Clinical Data at American Diabetes,Association Conference Highlighting Ability of Glufast to Maintain,Glycemic Control in Patients with Type 2 Diabetes 5
    (Date:8/20/2014)... approach to treating cancer - using Botox. A study ... Translational Medicine shows that cancer growth could be ... are linked to cancer stem cells. The approach thus ... treatment cheap, safe and efficient. The researchers have thus ... start testing on humans. , The nervous system is ...
    (Date:8/20/2014)... August 20, 2014 Quincy Bioscience, a ... 500|5000 list of the fastest growing private companies ... Ranking at No. 2,941, Quincy Bioscience is honored again ... the United States. , Quincy Bioscience is manufacturer of ... – a protein originally discovered in jellyfish and clinically ...
    (Date:8/20/2014)... DALLAS (PRWEB) August 20, 2014 Caddis ... track records of any healthcare real estate company in ... of medical assets valued at $500 million, including more ... of that significant growth, including expansions into new geographic ... expanded capabilities, company executives are pleased to announce an ...
    (Date:8/20/2014)... Beach, Florida (PRWEB) August 20, 2014 ... Florida, with the help of their experienced surgeons trained ... of patients to regain their lost or inaccurate vision. ... for performing Lasik surgery is making it possible for ... aging disease which occurs normally in people in the ...
    (Date:8/20/2014)... Antonio, TX (PRWEB) August 20, 2014 Texas ... their new study. The study will help test the effectiveness ... who suffer from high cholesterol may be eligible to participate ... too much cholesterol in the blood can lead to cardiovascular ... States. Lowering cholesterol can help reduce the risk of heart ...
    Breaking Medicine News(10 mins):Health News:Treating gastric cancer -- with Botox 2Health News:Quincy Bioscience Recognized in Inc. 500|5000 List of America’s Fastest Growing Companies for Third Consecutive Year 2Health News:Caddis Rebrands to Emphasize Its Growth, Expanded Capabilities 2Health News:Caddis Rebrands to Emphasize Its Growth, Expanded Capabilities 3Health News:Caddis Rebrands to Emphasize Its Growth, Expanded Capabilities 4Health News:Braverman Eye Center Now Offers Multifocal PresbyLasik in Florida by Trained Surgeons 2Health News:Texas Medical Research Associates Announce New Study 2
    ... President , , EAST ... SVNT ) today announced that its Board ... Committee")to oversee the regulatory and pre-launch activities for the ... comprised of independent Board members Lee S. Simon, M.D. ...
    ... CITY, Nov. 19 UCN, Inc.,(Nasdaq: UCNN ), ... one year renewable agreement for inContact(R) with a leading,healthcare provider ... , This new customer ... Response) solution with call routing between two of the company,s,contact ...
    ... Stayhealthy, Inc. and EF,Recovery announced today that they ... Fire Rescue Wellness Corporation to bring,revolutionary health and fitness ... "The health and safety of our ... Fire Chief of South Kitsap Fire Rescue. "As our ...
    ... This month the hit television,show ,Living in Style, ... in Style, is a half-hour news magazine television,series and ... clinically,proven ability to reduce body fat and increase lean ... premier brand of health supplements to,the consumer and utilizes ...
    ... People in the middle of,separation or divorce ... traditions are shattered; the hope and joy that ... depression. This year,s,economic downturn will add even more ... facing already-difficult financial circumstances. , ...
    ... LONDON, Nov. 19 With issues around patient comfort ... need to,consider patients, relief and welfare. This is leading ... are being used for a greater,number of patients and ... (Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO ) , ...
    Cached Medicine News:Health News:Savient's Board of Directors Forms a Board Committee to Oversee the Regulatory and Pre-Launch Activities for Pegloticase 2Health News:Savient's Board of Directors Forms a Board Committee to Oversee the Regulatory and Pre-Launch Activities for Pegloticase 3Health News:Savient's Board of Directors Forms a Board Committee to Oversee the Regulatory and Pre-Launch Activities for Pegloticase 4Health News:Savient's Board of Directors Forms a Board Committee to Oversee the Regulatory and Pre-Launch Activities for Pegloticase 5Health News:Savient's Board of Directors Forms a Board Committee to Oversee the Regulatory and Pre-Launch Activities for Pegloticase 6Health News:Savient's Board of Directors Forms a Board Committee to Oversee the Regulatory and Pre-Launch Activities for Pegloticase 7Health News:Savient's Board of Directors Forms a Board Committee to Oversee the Regulatory and Pre-Launch Activities for Pegloticase 8Health News:Leading Healthcare Provider Signs Agreement With UCN for inContact 2Health News:Washington Fire Firefighters Launch First of Its Kind Pilot Program on Health and Fitness 2Health News:Washington Fire Firefighters Launch First of Its Kind Pilot Program on Health and Fitness 3Health News:Clarinol(TM) CLA and Puregels(R) Featured on Hit Television Show 'Living in Style' 2Health News:Clarinol(TM) CLA and Puregels(R) Featured on Hit Television Show 'Living in Style' 3Health News:Holiday Season Amplifies Hurt of Separation and Divorce: Economic Woes Add to Pressure 2Health News:Patient Temperature Management Systems Enjoying Wider Usage 2Health News:Patient Temperature Management Systems Enjoying Wider Usage 3
    20L...
    ... new Finnpipette Focus from Thermo ... combine ergonomics with uncompromising performance. ... plate offers a custom fit ... new shorter tip cones allow ...
    ... fixed pipette is ideal for ... volume. Fixed volume FInnpipettes offer ... as other Finnpipette Digital pipettes: ... blow-out (1-40ul), Soft-touch tip ejection, ...
    ... includes fixed-volume, adjustable-volume, and multichannel models ... Research pro Pipette. Designed with a ... pipettes have earned a worldwide reputation ... with original Eppendorf pipette tips, they ...
    Medicine Products: